Prof Kausik Ray FMedSci
@ProfKausikRay
President European Atherosclerosis Society, Professor of Public Health, Imperial College London. Cardiologist focusing on preventing coronary artery disease
ID:965948717105909761
https://www.kausikray.com/ 20-02-2018 13:58:15
4,9K Tweets
5,2K Followers
1,0K Following
Follow People
The new call for applications for Competitive grants for EAS members is already open. Applications describing your proposed research project are welcome until September 13, 2024: eas.to/Grants2024 Prof Kausik Ray FMedSci
Many candidates to be ordinary member responsible for National Societies. Nice to see Dr Meral Kayikcioglu qualified for the final
Richard Ferraro Hooman Bakhshi Bailey Ann Estes SABOURETCardiologist Giuseppe Biondi-Zoccai Implausibly large effect sizes with sparse events are seldom replicable.
🧐Enjoy our work introducing #inclisiran
🎯Find out its unique mechanism, efficiencysafety profile supported by robust clinical trials.
🚀Inclisiran emerges as a first-in-class breakthrough in lipid-lowering therapies
#ASCVD #cholesterol Prof Kausik Ray FMedSci
tandfonline.com/doi/full/10.10…
4a) So we'll start with some updates on the seminal #CLEAR_Outcomes trial. Don't recall that? Refresh your memory & earn even more 🆓 #MedEd credit 🇺🇸🇨🇦🇪🇺🇬🇧from experts C. Michael Gibson MD Christopher Cannon, M.D. 🇺🇦 Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Prof Kausik Ray FMedSci at cardiometabolic-ce.com/category/lipid….
We are engineering the future of genetic medicine to enable #HealthForAll .
To do this, we are developing in vivo #CRISPR -based genetic medicines that can become standard of care treatments for highly prevalent diseases. Learn more this #WorldHealthDay at scribetx.com.
#ACC24 Gregory Schwartz reminds ud that Ezetimibe is still underutilized and can add substantial benefits to reduce ASCVD outcomes when added to statins or other LDLc lowering therapies! #CardioTwitter #Cardiology